GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Signatures Ltd (ASX:GSS) » Definitions » EV-to-FCF

Genetic Signatures (ASX:GSS) EV-to-FCF : -6.94 (As of May. 02, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Genetic Signatures EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Genetic Signatures's Enterprise Value is A$112.43 Mil. Genetic Signatures's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was A$-16.21 Mil. Therefore, Genetic Signatures's EV-to-FCF for today is -6.94.

The historical rank and industry rank for Genetic Signatures's EV-to-FCF or its related term are showing as below:

ASX:GSS' s EV-to-FCF Range Over the Past 10 Years
Min: -293.43   Med: -10.27   Max: 20.15
Current: -6.76

During the past 9 years, the highest EV-to-FCF of Genetic Signatures was 20.15. The lowest was -293.43. And the median was -10.27.

ASX:GSS's EV-to-FCF is ranked worse than
100% of 102 companies
in the Medical Diagnostics & Research industry
Industry Median: 27.61 vs ASX:GSS: -6.76

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-02), Genetic Signatures's stock price is A$0.705. Genetic Signatures's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.125. Therefore, Genetic Signatures's PE Ratio for today is At Loss.


Genetic Signatures EV-to-FCF Historical Data

The historical data trend for Genetic Signatures's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Signatures EV-to-FCF Chart

Genetic Signatures Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only -46.57 -23.32 -162.60 18.99 -2.87

Genetic Signatures Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 18.99 - -2.87 -

Competitive Comparison of Genetic Signatures's EV-to-FCF

For the Diagnostics & Research subindustry, Genetic Signatures's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genetic Signatures's EV-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Signatures's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Genetic Signatures's EV-to-FCF falls into.



Genetic Signatures EV-to-FCF Calculation

Genetic Signatures's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=112.426/-16.209
=-6.94

Genetic Signatures's current Enterprise Value is A$112.43 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Genetic Signatures's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was A$-16.21 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genetic Signatures  (ASX:GSS) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Genetic Signatures's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.705/-0.125
=At Loss

Genetic Signatures's share price for today is A$0.705.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Genetic Signatures's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.125.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Genetic Signatures EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Genetic Signatures's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Genetic Signatures (ASX:GSS) Business Description

Traded in Other Exchanges
N/A
Address
7 Eliza Street, Newtown, Sydney, NSW, AUS, 2042
Genetic Signatures Ltd proprietary PCR solutions and automated workflows routinely screen for multiple infectious diseases in a single test. Rapid and accurate results facilitate improved patient management and healthcare outcomes. GSS continues to expand its global reach with direct representation in Australia, Europe, and the United States, and growing distribution partnerships. The company operates under one business segment which is the research and commercialisation of identifying individual genetic signatures to diagnose diseases and disabilities.